Improvement in Patient-Reported Emotional Symptoms and Activity Limitations Due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3

    October 2025 in “ International Journal of Dermatology ”
    Ernest H. Law, Bintu Sherif, Arash Mostaghimi … Costel Chirila
    Studysummary In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 16

    1. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    2. Ritlecitinib: First Approval Drugs · 2023
    3. A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata Immunotherapy · 2023
    4. The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata Dermatology and Therapy · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs Clinical, Cosmetic and Investigational Dermatology · 2023
    7. The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity Journal of the European Academy of Dermatology and Venereology · 2023
    8. The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata Dermatology and Therapy · 2022
    9. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    10. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    11. Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata Dermatology and Therapy · 2021
    12. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review Dermatology and Therapy · 2021
    13. Evaluation of Stigma Toward Individuals With Alopecia JAMA Dermatology · 2021
    14. Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study Dermatology and therapy · 2021
    15. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    16. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012